Delayed-type skin reaction to the heparin-alternative danaparoid.
Eczematous, infiltrated plaques at the site of subcutaneously administered heparin appear to be common. Heparinoids cannot be recommended in general as a substitute for heparin or low molecular weight heparin because delayed-type skin reactions to these molecules can also occur, as demonstrated in this case report.
Szolar-Platzer
C
C
Department of Dermatology, University Hospital, Karl Franzens University Graz, Auenbruggerplatz 8, A-8036 Graz, Austria.
Aberer
W
W
Kränke
B
B
D000925:Anticoagulants / Q000009:adverse effects*; D002809:Chondroitin Sulfates / Q000009:adverse effects*; D003871:Dermatan Sulfate / Q000009:adverse effects*; D004338:Drug Combinations; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects; D006496:Heparinoids / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000009:adverse effects*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology*; D008875:Middle Aged
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid